Akebia Therapeutics Inc (AKBA) Institutional Ownership & 13F Filings (Q2 2026)

AKBA ranks #3384 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

AKBA is a disclosed holding of Cliff Asness (AQR Capital Management), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

171 institutions disclose a position in AKBA, but none treat it as a major bet — even Virtus Advisers, LLC, its most concentrated holder, allocates just 0.1% of its own portfolio to it.

Cliff Asness has added to its AKBA position for two straight quarters, increasing it by $9.4M to reach $10.4M today.

State Street has trimmed its AKBA position for two straight quarters, cutting it by $15.9M while still holding $6.1M.

AKBA is up 3.7% today, and institutions have been net buyers of $14.7M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

AKBA reported a net loss of $29.7M over the trailing twelve months.

• Not yet profitable — net loss of $29.7M over the trailing twelve months
• Revenue grew 7.5% year over year
• Net income improved year over year, from -$36.5M to -$29.7M
• Generated $68.0M in positive operating cash flow
• Current ratio of 1.55x — enough short-term assets to cover short-term liabilities
• Liabilities run 10.55x equity — a highly leveraged balance sheet worth noting